Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ZFPL1 drives hepatocellular carcinoma through CLDN3 in WNT signaling pathway

ABSTRACT: ZFPL1 drives hepatocellular carcinoma through CLDN3 in WNT signaling pathway

PROVIDER: PRJNA1160216 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30644423_1.fastq.gz	Fastqsanger.gz
	SRR30644423_2.fastq.gz	Fastqsanger.gz
	SRR30644424_1.fastq.gz	Fastqsanger.gz
	SRR30644424_2.fastq.gz	Fastqsanger.gz
	SRR30644425_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

ZFPL1 drives hepatocellular carcinoma via palmitoylation-dependent interaction with CLDN3 at Cys106

Project description:Massive studies have been applied in exploring the factors driving pathogenesis, progression and metastasis of hepatocellular carcinoma. However these studies were inefficient in disclosing the fundamental mechanism which promotes hepatocellular carcinoma. Zinc and zinc-finger proteins have been important in extensive biological processes for human. Supervised machine learning using bootstrapping algorithm on GEO and TCGA transcriptome data for hepatocellular carcinoma identified zinc-finger like protein ZFPL1 as potential hepatocellular carcinoma driver. Further studies validated ZFPL1 significantly promoted progression and metastasis of hepatocellular carcinoma. We performed RNA-seq on si-ZFPL1 xenograft tissue and identified CLDN3 as potential target gene for ZFPL1. Further experiments confirmed interaction between ZFPL1 and WNT signaling pathway markers. Conclusively, these studies indicated the effect and mechanism of ZFPL1 on promoting progression and metastasis of hepatocellular carcinoma and might gap the bridge between zinc-finger like proteins and hepatocellular carcinoma.

2024-10-19 | GSE277010 | GEO

Expression profile of hepatocellular carcinoma-matrix interaction

Project description:Expression profile of hepatocellular carcinoma-matrix interaction

| PRJNA735697 | ENA

ASCL2 drives sorafenib resistance through FSAN-mediated MDR1 palmitoylation

Project description:Addressing sorafenib resistance—a major barrier to effective treatment of hepatocellular carcinoma (HCC)—this study utilized patient-derived liver cancer stem cell (LCSC) models to elucidate the pivotal role of the transcription factor ASCL2 in maintaining stemness and driving drug resistance. Through integrated transcriptomic and epigenomic analyses, we discovered that ASCL2 orchestrates a resistance program by directly activating the transcription of fatty acid synthase (FASN) alongside palmitoyltransferases (ZDHHC5/9) and the multidrug resistance protein (MDR1), thereby transcriptionally "coupling" lipogenesis to protein modification. Mechanistically, ASCL2 promotes MDR1 palmitoylation and its subsequent membrane localization via FASN-driven palmitate production, ultimately leading to sorafenib resistance; conversely, pharmacological inhibition of palmitoylation disrupted MDR1 membrane localization and restored drug sensitivity in patient-derived LCSCs. These findings delineate a novel mechanism by which ASCL2 coordinates lipid metabolic reprogramming with post-translational modifications to drive therapeutic resistance, providing a potential interventional strategy to overcome sorafenib resistance by targeting LCSCs in HCC.

2026-04-17 | GSE326845 | GEO

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Project description:NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

| PRJNA903395 | ENA

Expression profile of hepatocellular carcinoma-matrix interaction

Project description:Scirrous hepatocellular carcinoma is a rare type of liver tumor that is charecterized by fibrous stroma, biliary differentiation of tumor cells, and poorer prognosis. In this study, we aim to analyze the efefcts of collagen 1 on signal tranduction pathway activation, gene expression profile, and phenotypic changes of hepatocellular carcinoma.

2021-06-08 | GSE176270 | GEO

NFE2L3 Drives Hepatocellular Carcinoma Proliferation via Regulating the Proteasome-Dependent Degradation of ISGylation p53 through interaction with TRIM25.

Project description:NFE2L3 Drives Hepatocellular Carcinoma Proliferation via Regulating the Proteasome-Dependent Degradation of ISGylation p53 through interaction with TRIM25.

| PRJNA867580 | ENA

i.e. RFX8 mediates DDX24 transcription in human hepatocellular carcinoma

Project description:Accumulating evidence suggests that DEAD-box proteins are essential in RNA metabolism and play pivotal roles in cancer progression. However, the mechanisms underlying how DDX24 drives hepatocellular carcinoma (HCC) remain largely unknown. In this study, we demonstrated that DDX24 was an oncogene and identified RFX8 as a DDX24 promoter-binding protein that transcriptionally upregulated DDX24 expression.

2021-01-29 | PXD022650 | Pride

ARID1B loss drives sorafenib resistance through transcriptional reprogramming in hepatocellular carcinoma

Project description:mRNA-seq was performed in HepG2 hepatocellular carcinoma cells to characterize transcriptional changes driven by ARID1B loss under sorafenib treatment. Wild-type (WT) and ARID1B-knockout (ARID1B-KO) HepG2 cells were treated with sorafenib (5 µM, 48 h) or DMSO vehicle, with three biological replicates per condition. DESeq2 interaction model identified ARID1B-dependent transcriptional responses to sorafenib. Preprint: https://doi.org/10.64898/2026.06.11.731725

2026-06-19 | GSE335769 | GEO

DDX24 promotes hepatocellular carcinoma progression via NCL dependent signaling pathway

Project description:Accumulating evidence suggests that DEAD-box proteins are essential in RNA metabolism and play pivotal roles in cancer progression. However, the mechanisms underlying how DDX24 drives hepatocellular carcinoma (HCC) remain largely unknown. In this study, we demonstrated that DDX24 was an oncogene and identified DDX24 promoted HCC development via interacting with NCL.

2021-01-29 | PXD023321 | Pride

ARID1B loss drives sorafenib resistance through transcriptional reprogramming in hepatocellular carcinoma

Project description:ARID1B loss drives sorafenib resistance through transcriptional reprogramming in hepatocellular carcinoma

| PRJNA1479416 | ENA